Taiga Biotechnologies, Inc.   Report issue

For profit Phase 1
Founded: Aurora CO United States (2006)

Organization Overview

First Clinical Trial
2016
NCT02860559
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Taiga Biotechnologies, Inc.

Active Ingredients

Drugs in Phase 1 Trials (3)

tbx-1400 (1 trial)

tbx-2400 (1 trial)

tbx-3400 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunologic Deficiency Syndromes (Phase 1)

Melanoma (Phase 1)

Neoplasms (Phase 1)

Severe Combined Immunodeficiency (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 3